Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
about
Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitusBrain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in HumansTopical review: a comprehensive risk model for disordered eating in youth with type 1 diabetesCombining incretin-based therapies with insulin: realizing the potential in type 2 diabetesEffects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysisTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsThe influence of clinical and genetic factors on the development of obesity in children with type 1 diabetes.Toward Big Data Analytics: Review of Predictive Models in Management of Diabetes and Its ComplicationsWeight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes.Evidence-based clinical use of insulin premixturesLiraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulinEvaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects.Neurobiology of food intake in health and disease.Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.Osteosarcopenic obesity: the role of bone, muscle, and fat on healthRemogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetesMaking Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics.Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitusInsulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes.Australian Nurse Practitioner Practice: Value Adding through Clinical Reflexivity.Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study.Emerging role of insulin with incretin therapies for management of type 2 diabetes.Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog.Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.Disordered eating behaviors in type 1 diabetic patients.Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.Chronic insulin therapy reduces adipose tissue macrophage content in LDL-receptor-deficient miceInsulin detemir for the treatment of obese patients with type 2 diabetes.Acute and subchronic in-vivo effects of Ferula hermonis L. and Sambucus nigra L. and their potential active isolates in a diabetic mouse model of neuropathic painUpdate on Safety Issues Related to Antihyperglycemic TherapyTreatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog.Intranasal insulin suppresses food intake via enhancement of brain energy levels in humansChanges in diabetes care indicators: findings from German National Health Interview and Examination Surveys 1997-1999 and 2008-2011.Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.
P2860
Q26471380-6F752704-1C47-40FC-8433-44E17BB22B39Q26739671-C7753903-AC30-4FC4-BDF3-B2C8CF90F6B3Q26865946-8B066543-F335-4721-8D14-18D0AF3A9B7EQ27004723-8E110B57-B24C-425A-B847-FB666ADFFF5CQ27012696-9C9AA6AD-FFA5-4E16-BBBE-4EC0A8A5DC54Q28077026-A6BA6688-46BE-487B-B8DC-B9797B726661Q30251829-3C6CD314-9D31-4526-97F5-7F3822BE3C04Q31005299-A867BB3B-FA4E-4EFC-A0B2-08D16223E05EQ31120318-C04B1B2A-AD19-4DEB-A5B7-8B9AA519A810Q33591271-74E290F2-8978-4625-9C4E-BCF3A4FEF284Q33603478-08ECA7CB-2E02-4F30-BB48-7B7B74F353E8Q33700904-BBAD8580-18B7-40A5-86B0-4DD8DF95A164Q33750654-C7FF1753-81FF-4B23-A966-5F328D3B4F00Q33825213-6CD7A608-957E-4599-B0C3-59755C6A65E1Q33835709-5115EF2E-57F0-41F3-8A71-33BBCBF6AAB2Q33888236-E19825A0-C602-48E6-B537-CDA1BC45ECA9Q34156977-07ECDC9F-E68E-43E3-A175-1A105D59B03BQ34301921-8222519D-CFF8-46EC-A181-5A1CE701DEE0Q34533154-3597CB95-3F2E-4FB2-BF47-7E627B854384Q34620581-654984A2-B6C8-4454-A168-2FAFF6C2E36DQ35048157-48B55874-033D-471E-A7E4-EC838699CDBCQ35060243-67095B08-1683-44C7-929F-58816C5D55C4Q35075299-0F4EDFB6-21D6-4205-B577-821567A8BF0FQ35101262-8BFC84A6-FECB-411F-89F4-2CC619C53804Q35214425-8B9EE078-FB51-46C5-825B-B6ED4355CC5DQ35331836-57C44D3C-C97B-4BB7-B2EB-4D0FBB470EC4Q35360786-6B413D02-3B24-4614-8B30-FF0B41FED7C6Q35411439-81E35E5D-7433-428F-98DA-1806F2B1FB99Q35549048-249050FD-A5A3-4337-AE9C-664A7BB226ABQ35594627-AE4D258B-BF65-42CA-9F53-512BDEDB2112Q35635199-46B01C8D-F2A1-4DF2-B6DC-0ACA4C1534A6Q35703041-FC15ADF8-C471-4F96-B6B8-E09F256DAB10Q35721251-C23F5481-C319-4E44-8C99-CAC127C6C83AQ35910429-4280E7E0-1454-4E0C-BFDB-A65F1BABA696Q36139042-05518A1C-4F67-4D25-81E8-6D1130A98E3DQ36182444-0F4F4378-6FA6-4172-BD6A-458E92C67BC4Q36301785-5B0040C8-5700-4ED0-89DA-6E1AA2703EEBQ36334638-B23AB69F-660E-4C12-8468-41C029E3EA39Q36449523-82E0FFEC-E58F-47F0-8B5E-C29D5FDD4672Q36498624-6D59EAF6-7DFE-468A-A41B-134BAF93D9C9
P2860
Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
@en
type
label
Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
@en
prefLabel
Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
@en
P2860
P1476
Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
@en
P2093
David Russell-Jones
Rehman Khan
P2860
P304
P356
10.1111/J.1463-1326.2006.00686.X
P577
2007-11-01T00:00:00Z